Chemistry: analytical and immunological testing – Clotting or clotting factor level tests
Reexamination Certificate
2011-08-30
2011-08-30
Wallenhorst, Maureen (Department: 1777)
Chemistry: analytical and immunological testing
Clotting or clotting factor level tests
C436S063000, C435S013000, C600S369000, C073S064410
Reexamination Certificate
active
08008086
ABSTRACT:
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.
REFERENCES:
patent: 3714815 (1973-02-01), Hartert
patent: 4148216 (1979-04-01), Do et al.
patent: 4193293 (1980-03-01), Cavallari
patent: 4312217 (1982-01-01), Hartert
patent: 4317363 (1982-03-01), Shen
patent: 4328701 (1982-05-01), Mau-Tung et al.
patent: 4599219 (1986-07-01), Cooper et al.
patent: 4695956 (1987-09-01), LeVeen et al.
patent: 5167145 (1992-12-01), Butler et al.
patent: 5223227 (1993-06-01), Zuckerman
patent: 5466582 (1995-11-01), Amiral
patent: 5523238 (1996-06-01), Varon et al.
patent: 5777215 (1998-07-01), Calatzis et al.
patent: 5854423 (1998-12-01), Venegas
patent: 5939276 (1999-08-01), Tomer
patent: 5972712 (1999-10-01), Baugh et al.
patent: 5972717 (1999-10-01), Aster et al.
patent: 6027904 (2000-02-01), Devine et al.
patent: 6060323 (2000-05-01), Jina
patent: 6225126 (2001-05-01), Cohen et al.
patent: 6537819 (2003-03-01), Cohen et al.
patent: 6613573 (2003-09-01), Cohen
patent: 7179652 (2007-02-01), Cohen et al.
patent: 2002/0178126 (2002-11-01), Beck et al.
patent: 2002/0197697 (2002-12-01), Abdelouahed et al.
patent: 2002/0198740 (2002-12-01), Roman et al.
patent: 2003/0073244 (2003-04-01), Cohen et al.
patent: 2005/0032142 (2005-02-01), Cohen
patent: 2007/0184508 (2007-08-01), Cohen
patent: 37 38 901 (1989-05-01), None
patent: 0 404 456 (1990-12-01), None
patent: 0 525 273 (1991-02-01), None
patent: 1 226 781 (2002-07-01), None
patent: 1 371 981 (2003-12-01), None
patent: 2 004 376 (1979-03-01), None
patent: WO-97/41432 (1997-11-01), None
patent: WO-00/49402 (2000-08-01), None
patent: WO-01/04159 (2001-01-01), None
patent: WO-01/50950 (2001-07-01), None
patent: WO-01/96879 (2001-12-01), None
patent: WO-02/054088 (2002-07-01), None
patent: WO-2004/031723 (2004-04-01), None
patent: WO-2004/081579 (2004-09-01), None
patent: WO-2004/092742 (2004-10-01), None
Gaetano et al., Effect of Platelets on Clot Structuration. A Thromebelastographic Study. Thrombosis Research. vol. 3, 1973, pp. 425-435.
Greilich et al. A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients. Anesth Analg., vol. 84, 1997, pp. 31-38.
Khurana et al., Monitoring Platelet Glycoprotein IIb/IIIa-fibrin Interation With Tissue Factor-Activated Thromboelastography. J Lab Clin Med, 1997, pp. 401-411.
Timmis et al., Advances in Antiplatelet Therapy in Coronary Artery Disease: Importance of the Platelet GPIIb/IIIa Receptor. Journal of Interventional Cardiology, vol. 10, No. 5, 1997, pp. 327-333.
Ultegra Rapid Platelet Function Assay (RPFA) Bedside Monitoring, Cath-Lab Digest, vol. 7, No. 6, 1999, pp. 1-3.
Ultegra System, Accumetrics Brochure, 2 pages.
Dambisya et al., Effects of the Platelet-Activating Factor Receptor Antagonist WEB 2086 on Whole Blood Coagulation and Fibrinolysis in a Thromboelastography Assay. Blood Coagulation and Fibrinolysis, vol. 6, 1995, pp. 733-737.
CSA Clot Signature Analyzer—Global Screening Device for Hemostasis, Xylum Corporation, 4 pages.
Orbitometer—The consequent development of the precursory Thrombo-Elastography (Hartert 1947) and of Resonance-Thrombography (Hartert 1977), Heinrich Amelung GmbH, 6 pages.
RoTEG Coagulation Analyzer, 1997 Dynabyte Medical, 2 pages.
RoTEG Coagulation Analyzer—whole blood coagulation analysis, 4 pages, 1996.
Elvi 816—Dual Channel, B1 Clot Thromboelastograph, Logos Scientific Inc., 2 pages.
TE-700—New Type Clot-Tracer Model, Erima, 4 pages (Japanese translation), 2 pages (English translation).
Muhl T Al., “Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically III Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy,” Journal of Intensive Care Medicine, vol. 17, No. 1, Jan./Feb. 2002, pp. 34-40.
Frenette et al., Effectiveness of Conjugated Estrogen in Orthotopic Liver Transplantation, Southern Medical Journal, vol. 91, Apr. 1998, pp. 365-368.
Ammar et al., “In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time,” Circulation, vol. 95, No. 3, Feb. 4, 1997, pp. 614-617.
Edwards et al., “Successful Use of Argatroban as a Heparin Substitute During Cardiopulmonary Bypass: Heparin-Induced Thrombocytopenia in a High-Risk Cardiac Surgical Patient,” The Annals of Thoracic Surgery, vol. 75, No. 5, May 2003. pp. 1622-1624.
Pravinkumar et al., HIT/HITT and alternative anlicoagulation: current concepts, British Journal of Anaesthesia, pp. 676-685.
Nguyen et al., A Web-Based Teaching Program for Laboratory Diagnosis of Coagulation Disorders, Arch. Pathol. Lab. Med., vol. 124, Apr. 2000, pp. 588-593.
Koster et al., “Recombinant Hirudin as an Alternative for Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia Type II: A 1-Year Experience in 57 Patients,” Journal of Cardiothoracic and Vascular Anestesia, vol. 14, No. 3, Jun. 2000, pp. 243-248.
Shore-Lesserson et al., Anesthesia and Analgesia (Abstract), vol. 88, Feb. 1999, p. 312.
Nowak, “The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, No. 4, pp. 173-183, 2003.
Koster et al., “Bivalirudin Monitored with the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass,” Anesthesia and Analgesia, vol. 96, No. 2, pp. 383-386. 2003.
International Search Report for Application No. PCT/US07/069655 dated Oct. 9, 2007.
Cohen Eli
Cohen Roslyn
Cora Healthcare, Inc.
Wallenhorst Maureen
LandOfFree
Protocol for monitoring direct thrombin inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protocol for monitoring direct thrombin inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protocol for monitoring direct thrombin inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665450